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ABSTRACT
IDENTIFYING RARE GENETIC VARIATION IN OBSESSIVE-COMPULSIVE
DISORDER
Sarah B. Abdallah, Carolina Cappi, Emily Olfson, and Thomas V. Fernandez. Child
Study Center, Yale University School of Medicine, New Haven, CT

Obsessive-compulsive disorder (OCD) is a neuropsychiatric developmental
disorder with known heritability (estimates ranging from 27%-80%) but poorly
understood etiology. Current treatments are not fully effective in addressing chronic
functional impairments and distress caused by the disorder, providing an impetus to study
the genetic basis of OCD in the hopes of identifying new therapeutic targets. We
previously demonstrated a significant contribution to OCD risk from likely damaging de
novo germline DNA sequence variants, which arise spontaneously in the parental germ
cells or zygote instead of being inherited from a parent, and we successfully used these
identified variants to implicate new OCD risk genes. Recent studies have demonstrated a
role for DNA copy-number variants (CNVs) in other neuropsychiatric disorders, but
CNV studies in OCD have been limited. Additionally, studies of autism spectrum
disorder and intellectual disability suggest a risk contribution from post-zygotic variants
(PZVs) arising de novo in multicellular stages of embryogenesis, suggesting these mosaic
variants can be used to study other neuropsychiatric disorders. In the studies presented
here, we aim to characterize the contribution of PZVs and rare CNVs to OCD risk.
We examined whole-exome sequencing (WES) data from peripheral blood of 184
OCD trio families (unaffected parents and child with OCD) and 777 control trios that
passed quality control measures. We used the bioinformatics tool MosaicHunter to

identify low–allele frequency, potentially mosaic single-nucleotide variants (SNVs) in
probands (OCD cases) and in control children. We then applied the XHMM tool to 101
of the OCD trio families and to the 777 control trio families, all generated with the same
capture library and platform, to identify CNVs.
The rate of all single-nucleotide PZVs per base pair was not significantly different
between OCD probands (4.90 x 10-9) and controls (4.93 x 10-9), rate ratio = 0.994, p = 1.
The rate of likely-damaging PZVs (those altering a stop codon or splice site) also is not
significantly different in OCD probands (1.45 x 10-9) than in controls (1.09 x 10-9), rate
ratio = 1.33, p = 0.653.
When examining CNVs, the proportion of children with at least one rare
duplication or deletion is not significantly different between OCD cases (0.869) and
controls (0.796), chi-square = 2.97, p = 0.0846. However, when considering deletions
separately from duplications, the proportion of children with at least one rare deletion is
higher in OCD trios (0.606) than in controls (0.448), chi-square = 8.86, p = 0.00292.
Although we did not detect a higher burden of PZVs in blood in individuals with
OCD, further studies may benefit from examining a larger sample of families or from
looking for PZVs in other tissues. The higher rate of de novo deletions in cases vs.
controls suggests they may contribute to OCD risk, but further work is needed to
experimentally validate the detected CNVs. We hope to eventually use these CNVs to
identify OCD risk genes that could provide jumping-off points for future studies of
molecular disease mechanisms.
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INTRODUCTION
Features of Obsessive-Compulsive Disorder
Obsessive-compulsive disorder (OCD) is a developmental neuropsychiatric
disorder with estimated prevalence of 1-3% worldwide. It is characterized by disabling
obsessions (intrusive, unwanted thoughts, sensations, or urges) and compulsions
(ritualized, repetitive behaviors that are difficult to control) (1). These symptoms can
cause distress, significantly compromise the affected individual’s social and occupational
functioning, and lead to increased risk of mortality, such that the World Health
Organization has named OCD among the ten most disabling medical conditions
worldwide (2). Although serotonergic antidepressants have been used in the treatment of
OCD for several decades, these pharmacologic treatments are not completely effective,
producing 30-50% reduction of symptoms in 60-80% of patients, and untreated OCD
tends to persist and become chronic (2, 3). The main barrier to developing more effective
therapeutic options for OCD is a poor understanding of its underlying etiology. For this
reason, there is great incentive to study the molecular basis of the disorder in the hopes of
identifying new therapeutic targets.
Like many neuropsychiatric disorders, OCD has high clinical heterogeneity, with
a wide range of possible symptoms and severity, such that different patients with the
disorder may have little to no phenotypic overlap. Efforts to better understand this
heterogeneity have used factor-analytic and clustering approaches to identify symptom
dimensions or subtypes in OCD (4-6). However, large-scale genetic studies generally
group together phenotypically divergent patients, potentially diluting genetic signals that
may be specific to a subgroup of patients. Further complicating efforts, OCD often is
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comorbid with other neuropsychiatric disorders, namely tic disorders, creating the
potential for confounding signals in genetic studies (5, 6).
OCD is thought to arise from a combination of genetic and environmental factors.
Twin and family studies have demonstrated substantial heritability of OCD, with
estimates around 27-47% for adult-onset cases and 40-80% for early-onset (childhood)
OCD (1, 7-15). Despite evidence for a significant genetic contribution to OCD
pathogenesis, risk gene discovery efforts have had little success so far, and the underlying
genetic basis of the disorder remains poorly understood. It is challenging to identify these
responsible genetic variants and genes because OCD is highly polygenic, meaning many
genes contribute to the disorder, and the combination of genetic factors contributing OCD
risk differs between patients (15-17). Current prevailing wisdom suggests a combination
of small-effect common variants and large-effect rare variants, either inherited from
parents or arising spontaneously, in hundreds of genes and within the intergenic space
contribute to OCD pathogenesis (16, 17). This complexity requires geneticists to draw
from different types of genetic information and methods of analysis to statistically
implicate risk genes.

Approaches to Studying OCD Genetics
Investigations into the genetic basis of OCD have taken several approaches to
uncovering the relevant genes, types of variation, and biological pathways involved in the
disorder (7, 15). The following section examines the relative success and findings of
these approaches to date.
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Association Studies
To date, few genome-wide association studies (GWAS) exploring the contribution
of common genetic variation to OCD have been conducted. Stewart et al. (18) performed
a meta-analysis of 1,465 cases, 5,557 ancestry-matched controls, and 400 parent-child
trios, while Mattheisen et al. (19) examined 1,406 individuals with OCD from 1,065
families. In the individual studies and a meta-analysis of both by the International OCD
Foundation (20), no loci reached genome-wide statistical significance (p < 5 x 10-8) in the
final analyses. While GWAS overall have been unsuccessful in identifying reproducible
genetic associations with OCD, common variants of small effect sizes are thought to
contribute partially to OCD heritability, and the lack of success with GWAS so far may
be due to insufficient sample sizes (16, 18, 19, 21). One would expect that a relatively
large proportion of loci approaching genome-wide significance would cross the
significance threshold in future GWAS with larger sample sizes. By this supposition,
overall trends or pathway enrichment among genes in these loci may still point to
relevant biology.
In contrast with the hypothesis-free nature of GWAS, candidate gene association
studies focus on single nucleotide polymorphisms (SNPs) within a preselected gene
hypothesized to be biologically relevant to a disease. While over 100 of these studies
have been conducted in OCD, few consistent findings have been reported (1, 8). Due to
issues of publication bias and failure to account for environmental and genetic
background of participants, among other factors, candidate gene studies are prone to false
positive results that largely have not been replicated (22-27). Further, many lack the
sample size needed to detect the small effects expected for complex disorders like OCD
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(26, 28). A meta-analysis of 230 polymorphisms from 113 candidate association studies
found a statistically significant association between OCD and alleles of two serotonergic
genes (5-HTTLPR and HTR2A) among all patients; among males only, it found a
significant association between OCD and COMT and MAOA alleles (28). Since the
publication of this meta-analysis, replicability of these results has been mixed, with
successful replication of the association with OCD for the common LA allele of 5HTTLPR but not for gene polymorphisms of HTR2A, COMT, and MAOA (29-31).
Unfortunately, because the genes or loci of interest are selected based on presupposition,
candidate gene studies are less useful in uncovering novel biology underlying disease
pathogenesis.

Rare Variation in Psychiatric Disease
While the aforementioned association studies attempt to pinpoint common
variation contributing to disease risk, other study designs leverage information about rare
variation to infer biology underlying disease. Investigation of rare variation in autism
spectrum disorder (ASD) has successfully associated several genes with ASD risk and
implicated specific brain regions and developmental timepoints in its pathogenesis (32),
suggesting these approaches hold promise.

Linkage Studies of Rare Inherited Variants
Because a child inherits about four to five million rare variants from their parents,
there is low statistical power to detect which of these variants fall in disease risk genes
and are contributing to disease risk in a patient cohort. Further, because inherited variants
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are subject to natural selection pressure while passing through generations, those that
persist are unlikely to have high damaging capacity (33). Thus, the utility of these
variants in implicating disease risk genes is limited to cases of families with multiple
affected individuals carrying very rare, large-effect inherited variants. In these families,
linkage studies can identify putative causal variants that associate with affected status
within the family (34). While several genome-wide linkage studies have been conducted
in OCD, few loci have reached genome-wide statistical significance and none have been
replicated (35-39).

De Novo Variation
De novo variants arise spontaneously in the child due to DNA replication errors
and are not inherited from parents. In contrast to inherited variants, de novo singlenucleotide variants arising in the germline (egg or sperm) or zygote are infrequent,
occurring on average 44-82 times throughout a person’s genome and only once or twice
in the coding regions, or exome (33). This rarity makes them much more useful for
detecting disease risk genes across cohorts. Genetic studies of other psychiatric disorders
have successfully harnessed de novo variants as a powerful means of identifying disease
risk genes (40-43). Recently, our group has applied this approach to OCD (see
preliminary studies) with success (44).

Post-Zygotic Variants
Post-zygotic variants (PZVs), de novo variants arising soon after conception
rather than in the parental germ cells, produce a mosaic child with the variant in only a
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fraction of cells throughout the body. Figure 1 depicts the different developmental
timepoints at which germline de novo variants and PZVs arise. In contrast to oncogenic
somatic mutations that can accumulate over an individual’s lifetime, PZVs occur in early
embryogenesis and theoretically should appear in multiple cell and tissue types
descended from the original embryonic cell. With high depths of coverage, nextgeneration sequencing allows for detection of potential mosaic variants based on the
observed mutant allele fraction, or the fraction of DNA segments with the variant allele at
a genomic position. Germline de novo variants theoretically should have a mutant allele
fraction of 50%, so any variants below a certain cutoff (e.g. 30%) are discarded as likely
technical artifacts (45). However, PZVs should have a mutant allele fraction far below
50% and likely produce true signal buried among these discarded variants.

A

germline

zygote

embryo

germline

zygote

embryo

heterozygote

B

mosaic
Figure 1. Consequences of spontaneous variants in offspring. (A) A germline de novo
variant arises in one parental germ cell and propagates through all cells of the child’s
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body, producing a child who is heterozygous for the variant. (B) After the zygote has
split into a multicellular embryo, a PZV arises in one of the cells and propagates through
the cell’s descendants, producing a child who is mosaic for the variant.

PZVs have been of recent interest in the study of several neuropsychiatric
disorders but are poorly understood within the context of these disorders. Recent studies
looking at previously identified de novo variants in ASD (46-49) and intellectual
disability (50) have shown that 5.8% and 6.5%, respectively, were in fact post-zygotic
rather than germline mutations. Several studies found that PZVs were enriched (more
frequent) in ASD probands (clinically affected individuals with unaffected parents and
siblings) compared to their unaffected siblings, and by one estimate the detected PZVs
contributed to 5.1% of ASD diagnoses, suggesting a role for somatic mosaicism in ASD
(46-49). These findings suggest that mosaic variation may provide a fruitful avenue to
examine the genetic underpinnings of neuropsychiatric disorders and may contribute
clinically meaningful genetic risk that previously was overlooked.

Structural (Copy Number) Variation
Examination of chromosomal structural variation, defined as variation in DNA
segments over one kilobase (kb) in length, has suggested a role in OCD pathogenesis.
Early cytogenetic and locus-specific studies of OCD cases identified inversions or
translocations of large DNA segments that converged on overlapping chromosomal
locations (15, 51). DNA microarrays, which provide better genome-wide resolution than
older cytogenetic techniques such as karyotyping, have improved detection of copy-
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number variants (CNVs; deletions or duplications of DNA sequences over one kb in
length) in recent years. Three microarray studies of CNVs in OCD found no overall
increased rate compared to controls. However, one study found that OCD cases harbored
a significantly higher rate of large deletions overlapping regions implicated in other
neurodevelopmental disorders, and the other two found a significantly higher rate of rare
CNVs affecting genes related to neurological function (11, 51, 52).
While microarrays have improved resolution compared to older techniques like
karyotyping and fluorescence in situ hybridization (FISH), they still are best at detecting
larger CNVs with a lower limit of about 30 kb in size. In contrast, high-throughput
sequencing approaches like WES can be used to more accurately detect small- to
medium-sized CNVs, which are more frequent in number compared to large CNVs (33,
53). Rare exonic deletions of 1-30 kb size have been estimated to contribute to disease
risk in up to 7% of ASD cases. Further, unlike large CNVs that typically contain multiple
genes, small exonic CNVs typically affected just one gene, making them useful for risk
gene discovery and pathway analysis (53). It is possible rare, smaller CNVs impart a
previously undetected contribution to OCD pathogenesis as well and can provide new
insights into underlying biology.

Preliminary Studies
Our group recently published the first analysis of rare inherited and germline de
novo single-nucleotide variants (SNVs) and insertion-deletion variants (indels) in patients
with OCD. The cohort collected for this study exclusively contained simplex probands
(affected individuals with no known affected first-degree relatives) to increase the
likelihood of detecting de novo variants. After quality control, analyses were conducted
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on whole-exome sequencing (WES) from peripheral blood in 184 OCD parent-proband
trios (families comprising two unaffected parents and one affected child) and in 777
control trios (unaffected parents and child). Among this cohort, likely-damaging germline
de novo variants were enriched in OCD probands compared to controls. These damaging
variants include likely gene-disrupting variants (LGD; nonsense, frameshift, or splice site
mutations) and missense mutations predicted to be damaging by the software PolyPhen2
(Mis-D). The study also estimated that de novo variants found within 335 genes
contributed to risk in 22% of cases (44). These findings suggest a significant contribution
of de novo SNVs and indels to OCD risk. Identification of these variants implicated two
new OCD risk genes, CHD8 and SCUBE1, based on gene-level recurrence, i.e. the
presence of at least two damaging (LGD or Mis-D) de novo variants in the same gene in
two unrelated probands.
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Figure 2. Germline de novo SNVs and indels in OCD probands vs. controls. Compared
to control children, OCD probands have significantly higher rates of Mis-D, LGD, and
total damaging germline de novo variants compared to controls. In contrast, synonymous
variants, which do not affect a gene’s protein product, are not expected to contribute to
OCD pathogenesis and are not more frequent in cases compared to controls. Figure
modified from Cappi et al. (44).

With an increased sample size of trios, we expect to identify additional risk genes,
particularly among the set of genes with one identified damaging variant to date. These
studies are underway. In the meantime, we can extend the value of our current sample by
identifying different types of genetic variants within our WES data. These variants may
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account for some missing information about OCD’s genetic basis and can provide
additional information to use in risk gene analyses.

Statement of Purpose and Specific Aims
We intend to build on our previous work using rare genetic variation detected in
WES of OCD trios to gain insights into the underlying biology of OCD. The overarching
purpose is to implement tools to identify two additional types of genetic variation from
our WES data, characterize the contribution of that variation to OCD risk, and use those
variants in statistical analyses to identify new potential OCD risk genes. These
approaches have not yet been described in the literature and could provide promising new
avenues to elucidate the genetic basis of OCD. This project will serve to fill a large
knowledge gap by providing insight into OCD genetics, paving the way for further
molecular and mechanistic studies of the disorder.

Aim 1: Characterize the Contribution of PZVs to OCD
The potential role of mosaic variation has not yet been described in the OCD
literature but could add to our understanding of the genetic etiology of OCD. We aim to
implement and optimize a computational approach to detect PZVs from WES data and to
characterize the burden of PZVs in OCD cases versus control probands. With our depth
of sequencing coverage in cases (76 reads per position on average) we can expect to
detect over 95% of SMVs with a mutant allele fraction of at least 20% and over 90% of
SMVs with a mutant allele fraction of at least 10% (54). Like our finding for damaging
germline de novo variants, we hypothesize that PZVs predicted to be damaging will have
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an increased burden (occur at a greater frequency) in OCD probands compared to
controls, suggesting a role for PZVs in OCD pathogenesis.

Aim 2: Characterize the Contribution of CNVs to OCD
The few studies that have explored the role of CNVs in OCD have used
microarray data, which has limited resolution compared to sequencing. We anticipate we
will be able to detect more CNVs from our WES data for OCD families. While WES
covers only the exome (the coding region of the genome) and cannot be used to detect
portions of CNVs in noncoding regions, we would expect the majority of the most
clinically significant CNVs to occur in coding regions so that they will severely impact
gene dosage. We aim to develop and optimize a computational approach to detect rare
inherited and de novo CNVs from our WES of OCD and control trios. Based on previous
findings in the literature, we expect to find an increased burden of deletions in probands
compared to controls.

Aim 3: Identify New OCD Risk Genes and Biological Pathways
We will use the variants detected in the first two aims to identify putative OCD
risk genes. Genes containing multiple germline or mosaic de novo variants or overlapping
novel de novo CNVs will be deemed to possibly contribute OCD risk. We will construct
networks of genes co-expressed across space and time in brain development and look for
networks enriched for OCD risk genes, which could point to specific brain regions and
developmental timepoints underlying OCD pathogenesis. Presuming correlated
expression levels across space and time suggest similar function or regulation for a set of
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genes, we can associate other genes within these networks with OCD as well (32). We
also will use gene ontology and pathway analysis tools to associate specific biological
pathways with the set of risk genes.

MATERIALS AND METHODS
Data collection and processing
Participant recruitment, sample collection, and whole-exome sequencing (WES)
were performed as described in Cappi et al., 2019 (44). In brief, we generated WES data
from peripheral blood DNA of 222 parent-child OCD trios collected from sites in
Toronto, Canada; São Paulo, Brazil; and New Haven, USA; and from a separate Tourette
International Collaborative Genetics study that included patients with both OCD and
chronic tics (55, 56). All samples were sequenced at the Yale Center for Genome
Analysis (YCGA) using the NimbleGen SeqCap EZExomeV2 (109 trios) or MedExome
(113 trios) capture libraries (Roche NimbleGen, Madison, WI) and the Illumina HiSeq
2000 platform (74-bp paired-end reads) (Illumina, San Diego, CA). These data were
compared to WES from peripheral blood DNA in 855 control trios without OCD from the
Simons Simplex Collection (57), sequenced at YCGA using the NimbleGen SeqCap
EZExomeV2 and the Illumina HiSeq 2000 platform. These WES data were aligned using
our lab’s well-validated analysis pipeline following the latest Genome Analysis Toolkit
(GATK) Best Practices guidelines (58). From this sample set, we retained 184 OCD trios
(117 male probands; 67 female) and 777 control trios (356 male children; 421 female)
that passed strict quality control measures, including removal of outlier trios based on
principal component analysis of sequencing quality metrics (44).
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Following sample collection and data processing, I performed all elements of the
work described below, including the development and implementation of variant (PZV
and CNV) calling approaches, mutation rate analyses, and risk gene and pathway
analyses.

Variant Calling
In-house computational pipelines built from pre-existing tools were developed to
detect PZVs and CNVs from WES data (Figure 2).
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A. Post-Zygotic Variant (PZV) Calling

B. Copy Number Variant (CNV) Calling

OCD Sequencing
Consortium
222 OCD trios

Simons Simplex
Collection
855 control trios

OCD Sequencing
Consortium
109 OCD trios

Simons Simplex
Collection
855 control trios

Nimblegen
EZExome v2 or
MedExome capture
library, Illumina
HiSeq 2000

Nimblegen
EZExome v2
capture library,
Illumina HiSeq
2000

Nimblegen
EZExome v2
capture library,
Illumina HiSeq
2000

Nimblegen
EZExome v2
capture library,
Illumina HiSeq
2000

184 OCD trios
passing QC

777 control trios
passing QC

101 OCD trios
passing QC

777 control trios
passing QC

Identify putative PZVs
with MosaicHunter

Identify putative CNVs
with XHMM

Filter to remove likely
false positive PZV calls

Classify rare inherited and de novo
CNVs with PLINK and PLINK/Seq

Mutation rate analysis

Mutation rate analysis

Figure 3. Variant calling pipelines for samples from the OCD Sequencing Consortium
(44) and Simons Simplex Collection (57). (A) 184 OCD trios and 777 control trios
passed quality control (QC) metrics for exome sequencing and all were included in the
PZV analysis. PZVs were detected with MosaicHunter (59) and subsequently filtered to
remove likely false positive variant calls. (B) 101 OCD trios and 777 control trios
sequenced with the same capture library were used to call CNVs, which were detected
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with XHMM and classified as transmitted (inherited) or de novo in the children using
PLINK and PLINK/Seq tools (60, 61).

PZV Calling with MosaicHunter
We called putative PZVs from our aligned and indexed WES for 184 OCD trios
and 777 control trios passing QC with MosaicHunter, a Bayesian-based genotyping tool
(Figure 3A). MosaicHunter was developed to call single-nucleotide mosaic variants in
non-cancer contexts, i.e. when a known normal control from the same individual is not
available to compared to the tissue of interest (59). We used the trio mode of the tool,
which incorporates WES from the parents into the calling algorithm, and the exome
mode, which employs a beta-binomial model that accounts for capture bias and overdispersion in WES to better fit the data. We applied these settings to our WES to identify
low–allele frequency, potentially mosaic SNVs in probands and in control children.
MosaicHunter was set to discard variants with a frequency of more than 0.05 in the
Single Nucleotide Polymorphism Database (62), variants with ≥10 sequencing reads in
the parents and ≥25 reads in the child, and variants falling in regions with indels or CNVs
in the child. All other parameters were left as their default settings, and reference genome
b37d5 was used (b37 human reference genome with decoy sequences). For each trio,
MosaicHunter generated an output file containing all calls found to violate Mendelian
inheritance, i.e. both de novo germline variants and PZVs. We discarded the output for
one outlier OCD trio with an excess of variants.
In addition to the filtering steps built into MosaicHunter, we applied inclusion
criteria to the output data to reduce the number of false positive PZVs in our final dataset.
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These criteria include: ≥0.7 posterior probability of being mosaic in the child, ≥1 child
likelihood ratio of mosaic vs. heterozygous, ≥0.5 posterior probability each parent does
not carry the alternate allele (reference homozygous genotype), no more than two reads
with the alternate allele in either parent, no duplicates of the variant across families, and
≤0.001 (<0.1%) frequency in non-Finnish European populations according to the Exome
Aggregation Consortium (ExAC) database (63). We removed all G>T variants with fewer
than 8 T alleles, as these are highly likely to be false positive calls caused by oxidative
damage to samples after collection (64).

CNV Calling with XHMM
We called putative CNVs from the same WES data, using 101 of the OCD trios
that were sequenced with the same capture library (Nimblegen EZ Exome V2) as the 777
control trios (Figure 3B). Sequencing read depths were calculated using GATK’s
DepthOfCoverage tool. Calls were generated using eXome-Hidden Markov Model
(XHMM), a statistical package designed specifically to detect CNVs from normalized
read-depth data from targeted sequencing (61). Members of one OCD trio and four
control trios were filtered by the XHMM default quality control methods and
consequently were not included in analyses. We then used an in-house pipeline following
a protocol (61) combining PLINK, Plink/Seq, and ANNOVAR software to annotate rare
CNVs (frequency <1% among all individuals in the sample set) in the children as
inherited or de novo. Plink/Seq quality thresholds for de novo calls were set at SQ ≥ 70
(high probability of a CNV in the child) and NQ ≥ 70 (high probability of no CNV in the
parents). Following annotation, we discarded maternal and paternal CNVs not transmitted
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to the child. We discarded one additional outlier OCD trio with an excess of CNV calls
(>20) in the child. After obtaining a set of de novo CNV calls, we used the AnnotSV
webtool (65) to identify de novo CNVs that were not present in the Database of Genomic
Variants (DGV; not previously detected in the human population) (66).

Burden Analysis
Mutation Rates of PZVs
Within cases and controls, we calculated the rates of single-nucleotide PZVs per
base pair. To account for differences in coverage between the two cohorts, we calculated
the number of callable base pairs per trio using the GATK DepthOfCoverage tool (58).
Callable bases were defined as those with a sequencing depth of at least 20 reads in all
three family members at that genomic position. To perform the burden analysis
(comparing mutation rates in cases vs. controls), we used the rateratio.test R package to
calculate mutation rate ratios with a two-sided p-value (67). We used the wANNOVAR
webtool using RefSeq hg19 gene definitions (analogous to b37d5, our reference genome)
to classify PZVs as LGD (adding/removing a stop codon or altering a canonical splice
site), nonsynonymous (predicted to alter a gene-encoded protein sequence), synonymous
(within the coding sequence but not affecting the protein product), or noncoding (68, 69).
For nonsynonymous variants, we used PolyPhen-2 to computationally predict the effects
of detected PZVs on protein function (70).
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Rates of CNVs
We calculated CNV rates as the number of CNVs per individual and as the
proportion of individuals in each cohort with at least one CNV. For both measures, we
performed the burden analysis with the rateratio.test R package as described above using
a two-sided p-value. Rate measurements were calculated together and separately for
deletions and duplications, and by size bin (<10 kb, 10-30 kb, >30 kb). We did not
perform a comparison of CNV lengths between cases and controls as the start and end
points (breakpoints) of CNVs may fall outside the exomic intervals targeted by WES,
rendering length measurements inaccurate.

Exploratory Risk Gene Pathway, and Expression Analyses
We used the wANNOVAR webtool to identify genes containing our putative
PZVs and the AnnotSV webtool to identify genes overlapping de novo CNVs. Genes
overlapping novel (not present in DGV) de novo CNVs were labeled as putative OCD
risk genes and used as the input gene list for our pathway analysis. Metascape was used
to perform pathway analyses using ontology terms pulled from KEGG Pathway, GO
Biological Processes, Reactome Gene Sets, Canonical Pathways and CORUM
knowledgebases (71). All known genes in the human genome were used in the
enrichment background to calculate an enrichment factor (the ratio between the observed
counts and the counts expected by chance) and an associated p-value. These analyses
were inputted into Cytoscape to generate and visualize an interactive enrichment network
of ontology terms for the gene list (72). Spatio-temporal expression analyses were
conducted using the Cell-type Specific Expression Analysis (CSEA) tool (73).
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RESULTS
Mutation Rates and Burden Analysis
PZV Rates
The rate of all single-nucleotide PZVs per base pair was not significantly different
between OCD probands (4.90 x 10-9) and controls (4.93 x 10-9), rate ratio = 0.994 (95%
confidence interval = 0.613-1.56), two-sided p = 1. Of the putative PZVs identified in
OCD probands, none are likely gene disrupting (LGD; alteration of a splice site or stop
codon) and 28% are missense mutations predicted by PolyPhen-2 to be probably
damaging (Mis-D). The rate of putative damaging PZVs (LGD and Mis-D) per base pair
also is not significantly different in OCD probands (1.45 x 10-9) than in controls (1.09 x
10-9), rate ratio = 1.33 (95% confidence interval = 0.475-3.27), two-sided p = 0.653
(Table 1). We observe no recurrence of PZVs in the same gene in unrelated probands
(Table 2).

Variant class

Variant count Mutation rate
(×10-9) per bp

Estimated
variants per
individual

Rate ratio
(95% CI)

pvalue

1

OCD Control OCD Control OCD Control
n=183 n=777 n=183 n=777 n=183 n=777
All

25

96

4.90

4.93

0.166

0.167

0.994
(0. 613-1.56)

Coding

18

76

3.72

4.14

0.126

0.140

0.899
0.797
(0.506-1.52)

Synonymous

6

16

1.24

0.872

0.0420 0.0295

1.42
0.605
(0.456-3.83)

Nonsynonymous

12

58

2.48

3.16

0.0840

0.785
0.594
(0.384-1.48)

0.107
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All Missense

12

55

2.48

3.00

0.0840

0.101

0.828
0.676
(0.404-1.56)

Mis-D

7

17

1.45

0.927

0.0490 0.0314

1.56
0.440
(0.548-3.96)

Mis-P

2

10

0.414

0.545

0.0140 0.0184

0.759
(0.0809-3.56)

Mis-B

3

28

0.621

1.53

0.0210 0.0516

0.407
0.176
(0.0791-1.32)

LGD

0

3

0

0.164

Damaging
(LGD + Mis-D)

7

20

1.45

1.09

Unknown

0

2

0

0.109

0

0.00553

0.0490 0.0369
0

0.00369

--a

1

--

1.33
0.653
(0.475-3.27)
--a

--

Table 1. PZVs are not enriched in OCD probands compared to unaffected controls.
Variants were annotated with Annovar, using RefSeq hg19 gene definitions.
“Nonsynonymous” variants include all missense and LGD variants. Mis-D are “probably
damaging” missense variants, Mis-P are “possibly damaging” missense variants, and
Mis-B are “benign” missense variants based on PolyPhen-2 scoring. LGD variants are
those adding/removing a stop codon or affecting a canonical splice site. “Unknown”
variants are included as coding variants but are not included in the synonymous or
nonsynonymous counts. Mutation rates were calculated as the number of variants divided
by the number of “callable” bases (see supplementary methods). Estimates of inherited
mutations per individual were calculated by multiplying the mutation rate by the size of
the RefSeq hg19 coding exome (33,828,798 bp). Mutation rates were compared with a
two-sided rate ratio test.
a

Rate ratio is not calculable.
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The mutant allele fractions of PZVs was not significantly different between the
OCD trios (mean = 0.236, SD = 0.126) and controls (mean = 0.213, SD = 0.107), t =
0.922, df = 119, two-sided p = 0.358. Additionally, when considering only PZVs with a
mutant allele fraction of at least 0.2, as in Dou et. al (49), the mutation rate for damaging
PZVs in OCD (6.21 x 10-10) was not significantly different from that in controls (3.82 x
10-10), RR= 1.63 (95% CI = 0.271-7.12), two-sided p = 0.696. No children in the OCD or
control trios harbored multiple likely damaging PZVs, so we did not perform a separate
calculation comparing the proportion of children with at least one PZV in each group.
Table 2 shows all putative PZVs detected in the OCD trios.

Position

Base pair
change

Variant type PolyPhen2
prediction

Gene(s)

Family
ID

1:10166307

G>A

missense

B

UBE4B

8186

2:64113007

G>T

missense

D

UGP2

8167

2:102018919

C>T

synonymous

RFX8

8097

2:118578877

G>A

intronic

DDX18

8144

2:179476243

G>A

missense

D

TTN

8214

4:887739

G>C

missense

D

GAK

8141

4:144620034

A>G

synonymous

FREM3

8197

5:172123965

C>G

intergenic

NEURL1B;
LOC101928093

8065

6:109312016

C>T

missense

SESN1

8074

7:48065402

G>A

intronic

SUN3

8206

7:99996911

C>T

intronic

PILRA

8167

8:22012961

G>T

synonymous

LGI3

8138

10:33140834

T>G

missense

P

CCDC7

8211

12:95604617

T>C

missense

B

FGD6

8183

D

23

16:69482126

A>G

intronic

CYB5B

8139

17:8381651

C>A

intronic

MYH10

8040

17:18167126

G>A

missense

B

MIEF2

8038

17:26488199

G>A

missense

D

NLK

8149

19:1083061

C>T

missense

P

ARHGAP45

8018

19:19765409

C>T

missense

D

ATP13A1

8094

20:33855171

C>T

synonymous

MMP24

8140

21:28793094

A>G

intergenic

ADAMTS5;
LINC00113

8168

22:51133459

C>T

synonymous

SHANK3

8042

X:110970140

C>T

synonymous

ALG13

8002

X:115303777

T>C

missense

AGTR2

8172

D

Table 2. Putative PZVs detected in OCD samples. For PolyPhen2 missense variant
predictions, D represents Mis-D or “probably damaging,” P represents Mis-P or “possibly
damaging,” and B represents Mis-B or “benign.” Two PZVs are found in the same child
from family 8167.

CNV Rates
The rate of all rare (de novo and inherited) CNVs per child is 2.42 in OCD cases
and 1.72 in controls, rate ratio = 1.41 (95% confidence interval = 1.23-1.62), two-sided p
= 2.65x10-6. The rate of rare de novo CNVs per child is 0.305 in OCD cases and 0.0854
in controls, rate ratio = 3.55 (95% confidence interval = 2.22-5.54), two-sided p =
2.97x10-7. For novel de novo CNVs not present in DGV, the rate per child is 0.192 in
OCD cases and 0.0492 in controls, rate ratio = 3.90 (95% confidence interval = 2.136.94), two-sided p = 1.91x10-5. These findings are shown in Table 3.
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Variant
class

All rare

Size
(kb)

CNV count
(CNVs per person)

Rate ratio
(95% CI)

p-value

OCD
99 trios

Control
773 trios

DEL

26
(0.263)

222
(0.287)

0.914
(0.584-1.38)

0.758

DUP

59
(0.596)

328
(0.424)

1.40
(1.05-1.86)

0.0242

DEL+DUP

85
(0.859)

550
(0.712)

1.21
(0.949-1.52)

0.126

DEL

22
(0.901)

115
(2.37)

1.49
(0.222-0.149)

0.120

DUP

39
(0.394)

179
(0.232)

1.70
(1.17-2.42)

0.00565

DEL+DUP

61
(0.616)

294
(0.380)

1.62
(1.21-2.14)

0.00140

DEL

35
(0.354)

156
(0.202)

1.75
(1.18-2.54)

0.00600

DUP

59
(0.596)

327
(0.423)

1.41
(1.05-1.86)

0.0230

DEL+DUP

94
(0.949)

483
(0.625)

1.52
(1.21-1.90)

0.000473

Total DEL

83
(0.838)

493
(0.638)

1.31
(1.03-1.66)

0.0288

Total DUP

157
(1.59)

834
(1.08)

1.47
(1.23-1.75)

2.65x10-5

Total DEL+DUP

240
(2.42)

1327
(1.72)

1.41
(1.23-1.62)

2.65x10-6

DEL

3
(0.0303)

8
(0.0103)

2.93
(0.500-12.2)

0.241

DUP

12
(0.121)

27
(0.0349)

3.47
(1.60-7.08)

0.00187

DEL+DUP

15
(0.152)

35
(0.0453)

3.35
(1.70-6.29)

0.000611

3

9

2.60

0.295

<10

10-30

>30

Rare de
novo

CNV type

<10

10-30

DEL

25
(0.0303)

(0.0116)

(0.453-10.4)

DUP

2
(0.0202)

8
(0.0103)

1.95
(0.202-9.78)

0.633

DEL+DUP

5
(0.0505)

17
(0.0220)

2.30
(0.662-6.48)

0.192

DEL

6
(0.0606)

6
(0.00776)

7.81
(2.09-29.2)

0.00215

DUP

4
(0.0404)

8
(0.0103)

3.90
(0.860-14.6)

0.0777

DEL+DUP

10
(0.101)

14
(0.0181)

5.58
(2.22-13.5)

0.000307

Total DEL

12
(0.121)

23
(0.0298)

4.07
(1.85-8.53)

0.000614

Total DUP

18
(0.182)

43
(0.0556)

3.27
(1.77-5.79)

0.000202

Total DEL+DUP

30
(0.305)

66
(0.0854)

3.55
(2.22-5.54)

2.97x10-7

<10

DEL

2
(0.0202)

5
(0.00647)

3.12
(0.297-19.1)

0.368

DUP

8
(0.0808)

19
(0.0246)

3.287
(1.25-7.86)

0.0167

DEL+DUP

10
(0.101)

24
(0.0310)

3.25
(1.39-7.06)

0.00707

DEL

2
(0.0202)

5
(0.00647)

3.12
(0.297-19.1)

0.368

DUP

2
(0.0202)

5
(0.00647)

3.12
(0.297-19.1)

0.368

DEL+DUP

4
(0.0404)

10
(0.0129)

3.12
(0.715-10.8)

0.131

DEL

4
(0.0404)

0
(0.000)

Inf
(5.15-Inf)

0.000332

DUP

1
(0.0101)

4
(0.00517)

1.95
(0.0396-19.7)

0.905

DEL+DUP

5
(0.0505)

4
(0.00517)

9.76
(2.10-49.2)

0.00320

8

10

6.25

0.000840

>30

Novel de
novo

10-30

>30

Total DEL

26
(0.0808)

(0.0129)

(2.14-17.6)

Total DUP

11
(0.111)

28
(0.0362)

3.07
(1.38-6.36)

0.00650

Total DEL+DUP

19
(0.192)

38
(0.0492)

3.90
(2.13-6.94)

1.91x10-5

Table 3. Rates of rare CNVs are higher in OCD probands compared to unaffected
controls. DEL = deletion; DUP = duplication. Significance threshold with Bonferroni
correction for multiple testing is 0.00139.

Considering deletions and duplications together, the proportion of children with at
least one CNV is not statistically significantly different between OCD cases and controls
for all rare and for novel de novo CNVs following multiple testing correction; however,
significantly more OCD cases have at least one rare de novo CNV compared to controls
(see Table 4). Looking only at deletions, the proportion of children with at least one rare
de novo or inherited deletion is higher in OCD trios (0.606) than in controls (0.448), chisquare = 8.86, p=0.00292. The proportion of children with at least one rare de novo
deletion is higher in OCD trios (0.111) than in controls (0.0298), chi-square=15.5,
p=0.000082. The proportion of children with at least one novel de novo deletion is higher
in OCD trios (0.0707) than in controls (0.0130), chi-square=15.3, p=0.000091. In
contrast, the proportion of children with at least one CNV is not significantly different
between cases and controls for all rare de novo or inherited duplications (OCD=0.747,
control=0.658, chi-square=3.14, p=0.0765), for rare de novo duplications (OCD=0.0909,
control=0.0543, chi-square=2.13, p=0.144), and for novel de novo duplications
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(OCD=0.0404, control=0.0349, chi-square=0.0767, p=0.782). These data are shown in
Figure 4 and Table 4.

Figure 4. Rare, rare de novo, and novel de novo deletion rates are increased in OCD
cases compared to controls. Within each CNV category, rates are calculated as proportion
of children with at least one CNV.
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Variant
class

All rare

Rare de
novo

Novel de
novo

CNV type

Proportion of children
with at least one CNV

Chi-square
statistic

p-value

OCD
(99 trios)

Control
(773 trios)

DEL

0.606

0.448

8.86

0.00292

DUP

0.747

0.658

3.14

0.0765

DEL+DUP

0.869

0.796

2.97

0.0846

DEL

0.111

0.0298

15.5

0.000082

DUP

0.0909

0.0543

2.13

0.144

DEL+DUP

0.182

0.084

10.1

0.00148

DEL

0.0707

0.0130

15.3

0.000091

DUP

0.0404

0.0349

0.0767

0.782

DEL+DUP

0.0909

0.0479

3.25

0.0713

Table 4. Proportion of children with at least one CNV. Deletions are enriched in OCD
cases vs. controls across all variant classes. Significance threshold with Bonferroni
correction for multiple testing is 0.00556.

The 19 putative novel de novo CNVs detected are present in nine OCD cases,
with one case containing eight of these CNVs and another containing four. In total, these
19 CNVs overlap 31 genes (Table 5).

Chromosome:start-end

CNV
type

CNV
size

Gene(s)

2:26587170-26611971

DUP

24801

SELENOI

2:100217897-100218083

DUP

186

AFF3

2:112536252-112545897

DEL

9645

ANAPC1

2:167055182-167085482

DEL

30300

SCN1A-AS1; SCN9A

29

2:170657471-170681107

DUP

23636

METTL5; SNORD3K; SSB

2:230456296-230456604

DUP

308

DNER

3:129546646-129547221

DUP

575

TMCC1

3:130305350-130318654

DEL

13304

COL6A6

5:80911292-80946158

DEL

34866

SSBP2

6:42897309-42897459

DUP

150

CNPY3; CNPY3-GNMT

7:26245988-26251794

DEL

5806

CBX3

8:101718922-101730116

DEL

11194

PABPC1

11:129780371-129780551

DUP

180

PRDM10

12:69124890-69279669

DEL

154779

CPM; LOC100130075; MDM2;
NUP107; SLC35E3

15:29367124-30092905

DUP

725781

APBA2; FAM189A1;
LOC100130111; NSMCE3; TJP1

15:45777361-45783079

DUP

5718

SLC30A4

17:71205668-71205907

DUP

239

FAM104A

18:45368198-45423127

DEL

54929

SMAD2

19:49926469-49926596

DUP

127

PTH2

Table 5. Putative novel de novo CNVs detected in OCD samples.

Pathway Analysis
For the list of 31 genes overlapping novel de novo OCD CNVs (the subclass of
CNVs with the highest rate ratio in the burden analysis), Metascape found eight ontology
terms that had a p-value < 0.01, had an enrichment factor > 1.5, and were associated with
at least three genes from the input list. Pathway analysis showed the highest enrichment
for the ontology terms cell cycle (p=0.00035), associated with SMAD2, MDM2, and
ANAPC1 genes; protein export from the nucleus (p=0.0010), associated with MDM2,
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SSB, and NUP107; and SUMO E3 ligases (p=0.0011), associated with MDM2,
NSMCE3, and NUP107. Figure 5 shows all eight terms mapped in a network based on
relatedness of terms, with terms with a similarity > 0.3 connected by edges (lines). Table
6 shows the genes contributing to each term and the corresponding p-value.

Figure 5. Pathway analysis of 31 genes overlapping novel de novo OCD CNVs. Nodes
are labeled by their corresponding gene ontology description, colored according to their
p-value (see legend), and connected by edges to show relatedness.

31

Ontology term

Gene hits

p-Value

Cell cycle

SMAD2; MDM2; ANAPC1

0.00035

Protein export from nucleus

MDM2; SSB; NUP107

0.0010

SUMO E3 ligases SUMOylate target
proteins

MDM2; NSMCE3; NUP107

0.0011

SUMOylation

MDM2; NSMCE3; NUP107

0.0012

Nuclear export

MDM2; SSB; NUP107

0.0013

Nucleobase-containing compound
transport

SSB; SLC35E3; NUP107

0.0024

Cell cycle checkpoints

MDM2; NUP107; ANAPC1

0.0042

Nucleocytoplasmic transport

MDM2; SSB; NUP107

0.0064

Table 6. Significant gene ontology terms from pathway analysis the set of 31 genes
overlapping novel de novo OCD CNVs. Genes (“hits”) contributing to each term and the
p-value for enrichment of the term are shown.

Clinical Features of Notable Cases
Five CNVs, each from a separate OCD patient, contribute to the eight significant
ontology terms from the pathway analysis (Table 7). All five patients have other
psychiatric comorbidities, notably Tourette Syndrome (TS) in all cases. The child from
family 8134 previously was found to have a de novo, germline, predicted-damaging
missense mutation in the CHD8 gene (44), though there is no history of ASD or
intellectual disability in the patient or in any close family members.
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Family CNV Gene(s)
ID
type
8134
DUP METTL5; SNORD3K; SSB

Sex

Age of
onseta
Male --b

8168
8171

DEL
DEL

Male 11
Male 5

8205

DEL

ANAPC1
CPM; LOC100130075;
MDM2; NUP107; SLC35E3
SMAD2

8221

DUP

APBA2; FAM189A1;
LOC100130111; NSMCE3;
TJP1

Male 8

Male 6

Other clinical
features
TS, ADHD, SAD,
irritability
TS
TS, ADHD
TS, current ADHD
symptoms, ASD/PDD,
congenital anomalies
TS, ADHD, ASD/PDD

Table 7. Clinical features of OCD cases with putative novel de novo CNVs contributing
to significant ontology terms. TS = Tourette Syndrome, ADHD = attention deficit
hyperactivity disorder, SAD = separation anxiety disorder, ASD/PDD = flagged for
autism spectrum disorders/pervasive developmental disorders. Congenital anomalies are
flagged in the phenotypic data but not further specified.
a

Age of OCD onset in years.

b

Data not available.

Expression Analysis
We performed an expression analysis of 31 genes overlapping novel de novo
OCD CNVs across brain regions and developmental time periods. No expression
networks within the CSEA brain region and development expression dataset were
enriched for these putative OCD risk genes. Of note, the Cerebellum Early Fetal network
contained 4 OCD risk genes (DNER, PRDM10, SCN9A, TMCC1), though it did not reach
statistical significance after multiple testing correction (uncorrected p=0.021, corrected
p=0.936).
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DISCUSSION
We successfully applied variant calling approaches to detect PZVs and CNVs in
WES. These variants still require experimental validation before we can use them in more
rigorous risk gene and other downstream analyses. However, we can begin to draw
inferences from our burden analyses about the potential role of these types of variation in
OCD pathogenesis and from our pathway analysis about potential biological mechanisms
significant in OCD.
In this study, we first aimed to characterize the contribution of PZVs to OCD. Our
burden analysis showed that, counter to our expectations, likely damaging PZVs were not
enriched in OCD cases compared to controls. This finding does not support our
hypothesis that damaging PZVs contribute to OCD pathogenesis. However, we may have
had difficulty detecting PZVs due to tissue- or cell-specificity. Somatic variants may be
present only in a specific tissue, and even within this tissue may affect only a subset of
cell types at certain developmental stages. A challenge to our approach is that by
studying whole blood, we may not detect tissue-specific mosaicism (for example, mosaic
variants present only in the brain). Furthermore, studying bulk tissue (blood) instead of
single cells may decrease our ability to detect mosaicism due to the presence of normal
cells in the tissue, which may overwhelm the signal from a minority of cells harboring
damaging mutations.
Additionally, our burden analysis may be hampered by insufficient power to
detect differences between the cohorts. Our power to detect differences in the rate of all
PZVs for cases and controls is estimated to be 0.828 based on rate ratios previously
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reported in the literature (see Power Calculations in Supplementary Methods). This
power should be sufficient (above 0.8) to detect differences, suggesting our failure to find
a difference in the rate of all PZVs reflects a true lack of statistical significance. This
mirrors our previous finding of no statistical difference in the rate of all germline de novo
variants in the same samples (44). However, we had hypothesized that we would see a
significantly higher rate of likely damaging PZVs in cases vs. controls. For this subset of
PZVs, our power to detect differences in mutation rate between the two groups is 0.423,
which is significantly below what we would like our power to be when using a
significance cutoff of 0.05. As we continue collecting WES for more OCD trios and our
sample size increases, we may have more power to detect significant differences in
damaging PZV burden.
The proportion of children with putative rare deletions of all classes was greater
for OCD patients than controls, while there was no difference in the proportion of OCD
and control children with rare duplications. This result is consistent with previous
microarray studies of CNVs in OCD (11, 51, 52). We might expect that deletions are
more likely to have a deleterious effect compared to duplications by inducing a
haploinsufficiency-like effect. However, duplications also could have a highly damaging
effect if their endpoint falls within a gene and disrupts the protein-coding region. Like the
PZVs, the detected putative CNVs should be validated experimentally to remove false
positives. If the enrichment of OCD patients with deletions holds after validation, this
finding would provide further evidence that rare deletions play a role in OCD
pathogenesis. Additionally, as we continue to sequence more OCD trios, we may detect
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additional risk genes and new biological pathways or expression networks enriched for
these genes.
Genes overlapping novel de novo CNVs in OCD patients are associated with
ontology terms related to cell cycle and nuclear transport. The associate with cell cycle
terms is consistent with findings that many genes related to neurodevelopmental
disorders play a role in neural stem cell proliferation and differentiation and that
particular genes are associated both with neurodevelopmental disorders and with cancers
(74). Similarly, many genes related to nuclear transport or nuclear localization, namely
those encoding transcription factors and chromatin modifiers, have been associated with
neurodevelopmental disorders (75-79). These findings are consistent with our previous
study of germline SNVs and indels in OCD WES. In the previous study we identified
CHD8, which encodes a DNA helicase that regulates gene expression through chromatin
remodeling, as a high-confidence OCD risk gene.
Like many patients with OCD, most of the OCD cases with CNVs contributing to
the significant ontology terms had multiple comorbid psychiatric disorders. All cases had
TS and four of the five had ADHD diagnoses or symptoms present at the time of
evaluation. Notably, two cases were flagged for a diagnosis of autism, one of which also
was flagged for congenital anomalies (unspecified in our available clinical data). These
cases highlight the challenges in teasing apart the contribution of genetic variants to OCD
and to comorbid features. Given recent evidence that OCD and TS have overlapping
genetic etiologies, future risk gene analyses in OCD should examine the overlap with
genes implicated in TS (44, 80). Future efforts to collect patients with OCD and without
comorbid disorders may help isolate potential OCD-specific genetic etiologies. Further,
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deep phenotyping of enrolled patients would allow us to interrogate genetic factors that
could contribute to the clinical heterogeneity of OCD. By attempting to sort patients
based on clinical phenotype, we could parse out any different genetic features between
OCD subtypes.

Future Directions
We intend to validate our detected likely damaging PZVs and de novo CNVs in
OCD cases with digital droplet PCR (ddPCR), a technique capable of validating very
low-frequency mosaic variants (81). In ddPCR, the DNA sample is diluted into droplets,
each containing one molecule of the target allele. A PCR reaction with fluorescent tags
marking the target region is run in each droplet, and quantification of the tag signal
allows calculation of allele frequency. Based on these validation results, we will optimize
the pipeline parameters to obtain high-confidence sets of variants. Following validations,
we will compare our set of detected CNVs in the WES data generated from our control
samples to microarray data previously generated in the same samples (57). Additionally,
we will compare the rates of CNVs detected in our WES for OCD patients to rates of
CNVs found in previous OCD studies that used microarray data. These comparisons will
test our hypothesis that detecting CNVs from WES data with our pipeline allows us to
detect more CNVs, particularly smaller ones, than can be detected using microarray data.
If our finding of CNV enrichment in OCD cases holds after validation, we will
use information about these variants to assess the level of significance of putative OCD
risk genes using the Transmission And De novo Association (TADA) statistical method.
TADA uses information about inherited and de novo variants to predict a gene’s
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likelihood of association with a disease and strongly implicates a gene in disease if
damaging de novo mutations are seen in the same gene in more than one unrelated
proband (82). This statistical method has been used to identify 99 high-confidence risk
genes in autism (83, 84), and we have used it to identify risk genes based on germline de
novo variants in OCD (44) and Tourette syndrome (56). By incorporating CNVs into this
model, we are likely to identify more OCD risk genes that will rise to the level of
statistical significance.
Long term, this research will help lay the groundwork for further research into the
molecular basis of OCD. Specific genes and biologic pathways implicated by our
analyses will provide jumping-off points to guide later studies examining molecular
mechanisms (e.g. animal and cell culture models). Ultimately, these mechanistic studies
will point to potential drug targets and will allow for development and testing of crucial
new therapeutic options for patients with OCD.
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SUPPLEMENTARY METHODS
Sequence Alignment
Sequence reads obtained from WES were aligned to the b37d5 human reference
genome using the Burrows-Wheeler Aligner tool, PCR duplicates were marked using
Picard's MarkDuplicates tool, and tab-delimited text file (BAM file) containing the
aligned exome data was generated (85). The BAM file for each individual’s exome was
used as the input for MosaicHunter and for XHMM.

Power Calculations
To estimate our power to detect differences in mutation frequency between our
OCD and control samples (86), we defined the following variables:

Group

Control children

Children with OCD

Mean callable base pairs

𝑡1

𝑡2

Sample size

𝑁1

𝑁2

Number of PZVs

𝑋1

𝑋2

Rate of PZVs per individual

𝜆1

𝜆2

The rate ratio of PZVs is 𝑅𝑅 =

𝜆2
𝜆1

. 𝑅𝑅0 = 1, representing the null hypothesis that the

mutation rates of the two groups are not statistically different. 𝑅𝑅𝑎 > 1, representing the
alternative hypothesis that the mutation rate in children with OCD is significantly greater
than that in control children.
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Assuming nonequal mutation rates for group 1 (control children) and group 2 (children
with OCD) with unconstrained maximum likelihood estimates, we can calculate the test
statistic for testing the ratio of two Poisson rates as

𝑊1 =

√𝑅𝑅0
𝑋2 − 𝑋1 (
)
𝑑
2

√𝑋2 + 𝑋1 (𝑅𝑅0 )
𝑑

where
𝑑=

𝑡1 𝑁1
𝑡2 𝑁2

Based on our samples, we can calculate
(2.506 ∗ 107 )777
𝑑=
= 3.818
(2.787 ∗ 107 )183
To calculate power, we use
𝑧1−𝛼 𝜎1 − 𝜇1
)
𝑃𝑜𝑤𝑒𝑟(𝑊1) = 1 − 𝜙 (
𝜎1
where
𝑅𝑅𝑎 𝑅𝑅0
) 𝑡1 𝑁1 𝜆1
𝜇1 = (
−
𝑑
𝑑
𝑑𝑅𝑅𝑎 + 𝑅𝑅𝑜 2
𝜎1 = √(
) 𝑡1 𝑁1 𝜆1
𝑑2
𝑧

𝜙(𝑧) = ∫ 𝑁𝑜𝑟𝑚𝑎𝑙(0,1)
−∞

Our significance threshold is α = 0.05, so our critical value 𝑧1−𝛼 = 1.645 using the
standard normal distribution and assuming infinite degrees of freedom.
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We estimated 𝑅𝑅𝑎 using the rate ratio for all mosaic variants found by Freed and Pevsner
in children with ASD compared to their unaffected siblings, which was 1.73 (46). This
allows us to calculate
𝜇1 = (

1.73
1
) (2.506 ∗ 107 )(777)(4.93 ∗ 10−9 ) = 18.35
−
3.818 3.818

3.818 ∗ 1.73 + 12
𝜎1 = √(
) (2.506 ∗ 107 )(777)(4.93 ∗ 10−9 ) = 7.077
3.8182
𝜙(

1.645 ∗ 7.077 − 18.35
) = 𝜙(−0.9479)
7.077

We calculate 𝜙(−0.9479) by integrating from -∞ to -0.9479 over a normal distribution
with mean = 0 and standard deviation = 1, giving
−0.9479

𝜙(−0.9479) =

∫

𝑁𝑜𝑟𝑚𝑎𝑙(0,1) = 0.172

−∞

This gives us
𝑃𝑜𝑤𝑒𝑟(𝑊1 ) = 1 − 0.172 = 0.828
for detecting differences in the rate of all PZVs. Repeating these calculations for our
ability to detect differences in rates of likely damaging PZVs using the rate ratio from
Freed and Pevsner for Mis-D and LGD mosaic mutations, which is 1.58, gives us a power
of 0.423.

Callable Bases
The number of “callable” bases within each trio was calculated as previously
described (44) and used to calculate PZV rates to minimize bias in calling variants

41
between case and control cohorts. Using the GATK DepthOfCoverage tool, we
calculated the number of bases covered at ≥ 20x in all family members, with base quality
≥20, and map quality ≥ 30 (the same thresholds required for GATK and de novo variant
calling). For each cohort, we summed the callable base pairs in every family. The sum of
coding and noncoding callable bases was used as the denominator for calculating rates of
all PZVs (5100562503 bases for 183 OCD trios and 19474297328 bases for 777 control
trios). The sum of only coding callable bases was used as the denominator for all other
rate calculations (4833549696 bases for 183 OCD trios and 18342070930 bases for 777
control trios).
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